Amphastar Pharmaceuticals stock hits 52-week low at 22.6 USD

July 08, 2025 11:37 PM AEST | By EODHD

Google News:

Amphastar Pharmaceuticals stock hits 52-week low at 22.6 USD — Image source: Kalkine Media

Recent News

CNH Joins the UN Global Compact and Reinforces Their Commitment to Sus...

The Ngāi Tahu Research Centre Has Entered Into a Strategic Partnership...

M4Markets Boosts Social Media Presence, Brings Real-Time Market Insigh...

M4Markets Spotlights the Big Trends: What's Shaping the Markets in 202...

Amphastar Pharmaceuticals (NASDAQ:AMPH) stock reached a 52-week low, trading at 22.6 USD. According to InvestingPro analysis, the company appears undervalued despite maintaining strong fundamentals with a P/E ratio of 7.88 and healthy liquidity shown by a current ratio of 2.95. This marks a significant downturn for the company, which has seen its stock price decline by 38.2% over the past year. The drop reflects ongoing challenges within the pharmaceutical sector and broader market conditions impacting Amphastar’s financial performance. However, the company maintains revenue growth of 8.05% and receives a "GREAT" financial health score from InvestingPro, which offers 5 additional key insights about Amphastar’s potential recovery.

Investors are closely monitoring the company’s strategic responses to these challenges as it seeks to stabilize and potentially rebound from this low point. In other recent news, Amphastar Pharmaceuticals reported its financial results for Q1 2025, revealing a mixed performance. The company missed analyst expectations with an earnings per share (EPS) of $0.51, below the projected $0.694, and reported revenue of $170.5 million, falling short of the forecasted $174.35 million. Additionally, Amphastar’s net income decreased to $25.3 million from $43.2 million in Q1 2024. Despite these financial challenges, the company experienced a 20% increase in sales of Primatene Mist, indicating strong market demand.

Furthermore, the FDA accepted Amphastar’s Biologics License Application for insulin aspart, marking a significant step in expanding its biosimilar insulin offerings. In related developments, JPMorgan downgraded Amphastar’s stock rating from Overweight to Neutral, citing ongoing challenges with the company’s product pipeline and regulatory hurdles. The firm also reduced its price target for Amphastar to $30.00 from $45.00, reflecting concerns about the company’s financial projections for 2025 and 2026. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.